Recent Updates
Recently added Catalysts
VNRX Positive Sentiment

Clinical utility of the Nucleosome levels in septic Acute Kidney Injury: improved classification and targeted intervention?

Monday, October 7, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The poster presented at ESICM 2024 by Neumann et al. discusses the clinical utility of Nucleosome levels in septic Acute Kidney Injury. It highlights the potential for improved classification and targeted interventions, which could lead to better patient management. The findings may have significant implications for future treatment protocols.
Price reaction · baseline $17.66 (2024-10-04 close) · hit pre-market · 7 other VNRX headline(s) in the window, move may be shared
day 0 close
-11.1%
day 1
-12.5%
day 3 · peak
-20.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • The poster presents promising data on Nucleosome levels.
  • It suggests improved classification for septic Acute Kidney Injury.
  • Targeted intervention strategies may enhance patient outcomes.

Full Press Release Details

Poster titled: Clinical utility of the Nucleosome levels in septic Acute Kidney Injury: improved classification and targeted intervention?
Presented at: ESICM 2024
Neumann et al

Related Articles

• Press Releases Data Showing the Prognostic Value of its Nu.Q® Cancer Test
• Poster & Publications Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

Data Showing the Prognostic Value of its Nu.Q® Cancer Test

Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

• Share
• Tweet
• Share on Facebook
• Share

Subscribe for Volition product updates .

Or, click here for Investor Updates and press releases .

" * " indicates required fields

Frequently Asked Questions

What was the focus of the poster presented at ESICM 2024?

The poster focused on the clinical utility of Nucleosome levels in septic Acute Kidney Injury.

Who presented the poster on Nucleosome levels?

The poster was presented by Neumann et al.

What potential benefits were discussed in the poster?

The poster suggests improved classification and targeted interventions for septic AKI.

Where was the poster presented?

It was presented at the ESICM 2024 conference.

ShareAdd on Google
Tags: VNRX Viatris Investor Conferences Healthcare Nucleosome levels septic Acute Kidney Injury ESICM 2024 Neumann et al clinical utility
Last updated: Oct 7, 2024

Biotech snapshot

Cash runway
$3M liquidity · $2M/mo burn
~1 mo
High dilution risk